Scientists identify germline signature that predicts side effects from anti-PD1/PDL1 checkpoint therapy
Investigators have identified a germline biomarker signature that successfully predicts which patients will suffer serious side effects that occur in up to 3 in ten patients on anti-PD1/PDL1 therapy, a promising new approach to treating cancer.
Materials provided by University of California – Los Angeles Health Sciences. Note: Content may be edited for style and length.
Source link aaaaa